FDA's Stem Cell Oversight Faces Pivotal Test In DC Circ.
By Jeff Overley (October 22, 2013, 8:46 PM EDT) -- The D.C. Circuit is poised to shape the future of stem cell therapy as it mulls the extent of the U.S. Food and Drug Administration's power to regulate the potentially revolutionary field, likely determining whether numerous treatments can avoid costly and time-consuming approval processes, experts say.
At oral arguments this week, judges have seemed skeptical of the appeal from Regenerative Sciences LLC, a Colorado clinic accusing the FDA of improperly trying to police the practice of medicine by declaring its stem cell injections to be a drug instead of a procedure.
Few rulings appear to exist on the subject, and given...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!